Literature DB >> 19361604

Characteristics in phenotypic manifestations of genetically proved Marfan syndrome in a Japanese population.

Koichi Akutsu1, Hiroko Morisaki, Satoshi Takeshita, Hitoshi Ogino, Masahiro Higashi, Toshiya Okajima, Tsuyoshi Yoshimuta, Yoshiaki Tsutsumi, Hiroshi Nonogi, Takayuki Morisaki.   

Abstract

Diagnosis of Marfan syndrome (MS) is made according to the Ghent nosology, which is based on data from European and American populations. The validity of applying the Ghent nosology to other than Western populations is an ongoing discussion because there may be racial differences in basic physical features. The validity of applying the Ghent nosology to patients other than Westerners suspected of having MS was examined. One hundred thirteen Japanese patients who were suspected of having MS and underwent genetic analysis were examined to see whether they fulfilled the Ghent nosology. Of 113 patients, MS was diagnosed in 58 patients/51 probands. Of these 51 probands, 46 (90%) showed mutations in the Fibrillin-1 gene(FBN1) and were enrolled in this study. The frequency of each manifestation of Ghent nosology in the Japanese population was compared with those reported in the FBN1 Universal Mutation Database that was mainly obtained from the Western population (n = 1,013 probands). Frequencies were lower in the Japanese population than the Western population of the manifestations of arm span to height ratio >1.05 (20% vs 55%; p <0.01), scoliosis (40% vs 53%; p <0.05), reduced extension at elbows (2% vs 16%; p <0.05), and joint hypermobility (46% vs 63%; p <0.05). In conclusion, we found a lower frequency of skeletal manifestations of MS in Japanese patients than reported in the database for Western patients with MS. It was possible that the diagnosis of MS according to the Ghent nosology for Japanese patients was underestimated, especially for skeletal involvements.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361604     DOI: 10.1016/j.amjcard.2008.12.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

Authors:  Alain Li-Wan-Po; Bart Loeys; Peter Farndon; David Latham; Caroline Bradley
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  Spinal imaging features in Japanese patients with Marfan syndrome: a case-control study.

Authors:  Eri Hayashida; Daisuke Utsunomiya; Akira Sasao; Tsuyoshi Yasuda; Toshinori Hirai; Hideaki Yuki; Seitaro Oda; Joji Urata; Akihiko Arakawa; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2014-01-30       Impact factor: 2.374

Review 3.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

4.  Disease-specific Growth Charts of Marfan Syndrome Patients in Korea.

Authors:  Younghee Kwun; Su Jin Kim; Jieun Lee; Tsuyoshi Isojima; Doo-Seok Choi; Duk-Kyung Kim; June Huh; I-Seok Kang; MiSun Chang; Sung Yoon Cho; Young Bae Sohn; Sung Won Park; Dong-Kyu Jin
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

5.  Clinical Characteristics of Marfan Syndrome in Korea.

Authors:  A Young Lim; Ju Sun Song; Eun Kyoung Kim; Shin Yi Jang; Tae-Young Chung; Seung-Hyuk Choi; Kiick Sung; June Huh; I-Seok Kang; Yeon Hyeon Choe; Chang-Seok Ki; Duk-Kyung Kim
Journal:  Korean Circ J       Date:  2016-10-24       Impact factor: 3.243

6.  Analysis of Protrusio Acetabuli Using a CT-based Diagnostic Method in Korean Patients with Marfan Syndrome: Prevalence and Association with Other Manifestations.

Authors:  Kwang Jin Chun; Jeong Hoon Yang; Shin Yi Jang; Seung Hwa Lee; Hye Bin Gwag; Tae-Young Chung; June Huh; Chang-Seok Ki; Kiick Sung; Seung-Hyuk Choi; Sung Mok Kim; Yeon Hyeon Choe; Duk-Kyung Kim
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.